Oil prices rise on talk of Russia sanctions; bouncing off recent lows
Lisa Lynn Decker, Chief Business Officer of IGM Biosciences (NASDAQ:IGMS), sold 951 shares of common stock on June 16, 2025. The transaction comes as the company’s stock has declined over 83% in the past six months, currently trading at $1.17, just above its 52-week low of $0.92. The shares were sold at a weighted average price of $1.1992, for a total value of $1,140. The transactions were executed in multiple trades at prices ranging from $1.17 to $1.22.
The sale was to cover tax withholding obligations related to the vesting of restricted stock units. Following the transaction, Decker directly owns 72,578 shares of IGM Biosciences.
In other recent news, IGM Biosciences announced the termination of its collaboration and license agreement with Genzyme Corporation, a Sanofi (NASDAQ:SNY) entity. This agreement, which began on March 28, 2022, was focused on developing IgM antibodies for diseases like cancer and immunological disorders. The termination notice was received on May 5, 2025, and will be effective 30 days from that date. In response to this development, IGM Biosciences has implemented significant cost-cutting measures, including an 80% reduction in its workforce and the closure of most laboratory and office spaces. The company is actively seeking strategic alternatives and reorganization options to address the situation. This decision marks a notable shift in IGM Biosciences’ operations and financial outlook. The company has not yet determined its strategic next steps as it navigates these changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.